Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: Implications for pathogenesis

Journal of Experimental Medicine

Volumn 185, Issue 1, 1997, Pages 71-79

  Casciola Rosen, Livia ^a   Wigley, Fredrick ^a   Rosen, Antony ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN;

ANTIBODY RESPONSE; APOPTOSIS; ARTICLE; BLOOD VESSEL REACTIVITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; ISCHEMIA; OXIDATION REDUCTION REACTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN MODIFICATION; REPERFUSION; SCLERODERMA;

AUTOANTIGENS; BINDING SITES; CHELATING AGENTS; COPPER; DNA TOPOISOMERASES, TYPE I; ETHYLDIMETHYLAMINOPROPYL CARBODIIMIDE; HELA CELLS; HUMANS; HYDROXYL RADICAL; IRON; ISCHEMIA; KERATINOCYTES; METALS; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; REPERFUSION; SCLERODERMA, SYSTEMIC; ZINC;

EID: 0031025143     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.185.1.71     Document Type: Article

References (50)

1. Radic, M.Z., and M. Weigert. 1994. Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annu. Rev. Immunol. 12:487-520.
2. Diamond, B., J.B. Katz, E. Paul, C. Aranow, D. Lustgarten, and M.D. Scharff. 1992. The role of somatic mutation in the pathogenic anti-DNA response. Annu. Rev. Immunol. 10: 731-757.
3. Sercarz, E.E., P.V. Lehmann, A. Ametani, G. Benichou, A. Miller, and K. Moudgil. 1993. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 11:729-766.
4. Lanzavecchia, A. 1995. How can cryptic epitopes trigger autoimmunity? J. Exp. Med. 181:1945-1948.
5. Gammon, G., and E.E. Sercarz. 1989. How some T cells escape tolerance induction. Nature (Lond.). 342:183-185.
6. Mamula, M.J. 1993. The inability to process a self-peptide allows autoreactive T cells to escape tolerance. J. Exp. Med. 177:567-571.
7. Bockenstedt, L.K., R.J. Gee, and M.J. Mamula. 1995. Self-peptides in the initiation of lupus autoimmunity. J. Immunol. 154:3516-3524.
8. Salemi, S., A.P. Caporossi, L. Boffa, M.G. Longobardi, and V. Barnaba. 1995. HIVgp120 activates autoreactive CD4-specific T cell responses by unveiling of hidden CD4 peptides during processing. J. Exp. Med. 181:2253-2257.
9. Watts, C., and A. Lanzavecchia. 1993. Suppressive effect of an antibody on processing of T cell epitopes. J. Exp. Med. 178:1459-1463.
10. Simitsek, P.D., D.G. Campbell, A. Lanzavecchia, N. Fairweather, and C. Watts. 1995. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J. Exp. Med. 181:1957-1963.
11. Casciola-Rosen, L.A., G. Anhalt, and A. Rosen. 1994. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med. 179:1317-1330.
12. Casciola-Rosen, L.A., D.K. Miller, G.J. Anhalt, and A. Rosen. 1994. Specific cleavage of the 70-kDa protein component of the U1 small nuclear ribonucleoprotein is a characteristic biochemical feature of apoptotic cell death. J. Biol. Chem. 269:30757-30760.
13. Casciola-Rosen, L.A., G.J. Anhalt, and A. Rosen. 1995. DNA-dependent protein kinase is one of a subset of autoantigens specifically cleaved early during apoptosis. J. Exp. Med. 182:1625-1634.
14. Casciola-Rosen, L.A., D.W. Nicholson, T. Chong, K.R. Rowan, N.A. Thornberry, D.K. Miller, and A. Rosen. 1996. Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. J. Exp. Med. 183:1957-1964.
15. Belch, J.J.F. 1991. Raynaud's phenomenon: its relevance to scleroderma. Ann. Rheum. Dis. 50:839-845.
16. Norton, W.L., and J.M. Nardo. 1970. Vascular disease in progressive systemic sclerosis (scleroderma). Ann. Intern. Med. 73:317-324.
17. McCord, J.M. 1985. Oxygen-derived free radicals in postischemic tissue injury. N. Engl. J. Med. 312:159-163.
18. Zweir, J.L. 1988. Measurement of superoxide-derived free radicals in the repertused heart. J. Biol. Chem. 263:1353-1357.
19. Oliver, C.N., P.E. Starke-Reed, E.R. Stadtman, G.J. Liu, J.M. Carney, and R.A. Floyd. 1990. Oxidative damage to brain proteins, loss of glutamine synthetase activity, and production of free radicals during ischemia/reperfusion-induced injury to gerbil brain. Proc. Natl. Acad. Sci. USA. 87:5144-5147.
20. Herrick, A.L., F. Rieley, D. Schofield, S. Hollis, J.M. Braganza, and M.I.V. Jayson. 1994. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J. Rheumatol. 21:1477-1483.
21. Stein, C.M., S.B. Tanner, J.A. Awad, L.J.I. Roberts, and J.D. Morrow. 1996. Evidence for free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum. 37:1146-1150.
22. Davies, K.J.A. 1987. Protein damage and degradation by oxygen radicals. I. General aspects. J. Biol. Chem. 262:9895-9901.
23. Stadtman, E.R. 1990. Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radical Biol. Med. 9:315-325.
24. Youngman, R.J. 1984. Oxygen activation: is the hydroxyl radical always biologically relevant? TIBS (Trends Biochem. Sci.) 280-283.
25. Halliwell, B., and J.M.C. Gutteridge. 1986. Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch. Biochem. Biophys. 246:501-514.
26. Levine, R.L., C.N. Oliver, R.M. Fulks, and E.R. Stadtman. 1981. Turnover of bacterial glutamine synthetase: oxidative inactivation precedes proteolysis. Proc. Natl. Acad. Sci. USA. 78:2120-2124.
27. Levine, R.L. 1983. Oxidative modification of glutamine synthetase. II. Characterization of the ascorbate model system. J. Biol. Chem. 258:11828-11833.
28. Creeth, J.M., B. Cooper, A.S. Donald, and J.R. Clamp. 1983. Studies of the limited degradation of mucus glycoproteins. The effect of dilute hydrogen peroxide. Biochem. J. 211: 323-332.
29. Cooper, B., J.M. Creeth, and A.S. Donald. 1985. Studies on the limited degradation of mucus glycoproteins. The mechanism of the peroxide reaction. Biochem. J. 228:615-626.
30. Shero, J.H., B. Bordwell, N.F. Rothfield, and W.C. Earnshaw. 1986. High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science (Wash. DC). 231:737-740.
31. Rodriguez-Sanchez, J.L., C. Gelpi, C. Juarez, and J.A. Hardin. 1987. Anti-NOR 90: a new autoantibody in scleroderma that recognizes a 90-kDa component of the nucleolus-organizing region of chromatin. J. Immunol. 139:2579-2584.
32. Hirakata, M., Y. Okano, A. Suwa, T.A. Medsger, Jr., J.A. Hardin, and J. Craft. 1993. Identification of autoantibodies to RNA polymerase II. Occurrence in systemic sclerosis and association with autoantibodies to RNA polymerases I and III. J. Clin. Invest. 91:2665-2672.
33. Tan, E.M. 1991. Autoantibodies in pathology and cell biology. Cell. 67:841-842.
34. Fucci, L., C.N. Oliver, M.J. Coon, and E.R. Stadtman. 1983. Inactivation of key metabolic enzymes by mixed function oxidation reactions: possible implications in protein turnover and ageing. Proc. Natl. Acad. Sci. USA. 80:1521-1525.
35. Stadtman, E.R. 1993. Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu. Rev. Biochem. 62:797-821.
36. Rana, T.M., and C.F. Meares. 1990. Specific cleavage of a protein by an attached iron chelate. J. Am. Chem. Soc. 112: 2457-2458.
37. Brendel, V., J. Dohlman, B.E. Blaisdell, and S. Karlin. 1991. Very long charge runs in systemic lupus erythematosus-associated autoantigens. Proc. Natl. Acad. Sci. USA. 88:1536-1540.
38. Tandler, C.J. 1956. An acid-soluble component of the nucleolus: the cytochemical specificity of the "lead-acetate reaction". J. Histochem. Cytochem. 4:331-340.
39. Pihl, E. 1968. Recent improvements of the sulfide-silver procedure for ultrastructural localization of heavy metals. J. Microsc. (Paris). 7:509-520.
40. Studzinski, G.P. 1965. Selective binding of zinc by basic proteins of the HeLa cell nucleolus. J. Histochem. Cytochem. 13: 365-375.
41. Tandler, C.J., and A.J. Solan. 1969. Nucleolar orthophosphate ions: electron microscope and diffraction studies. J. Cell Biol. 41:91-108.
42. Wu, J., D.M. Perrin, D.S. Sigman, and H.R. Kaback. 1995. Helix packing of lactose permease in Escherichia coli studies by site-directed chemical cleavage. Proc. Natl. Acad. Sci. USA. 92:9186-9190.
43. Rana, T.M., and C.F. Meares. 1991. Transfer of oxygen from an artificial protease to peptide carbon during proteolysis. Proc. Natl. Acad. Sci. USA. 88:10578-10582.
44. Zaychikov, E., E. Martin, L. Denissova, M. Kozlov, V. Markovtsov, M. Kashlev, H. Heumann, V. Nikiforov, A. Goldfarb, and A. Mustaev. 1996. Mapping of catalytic residues in the RNA polymerase active center. Science (Wash. DC). 273:107-109.
45. Studzinski, G.P., and R. Love. 1964. Nucleolar organelles shown by lead precipitation in unfixed cultured cells. Stain Technol. 39:397-401.
46. Kuwana, M., T.A. Medsger, Jr., and T.M. Wright. 1995. T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors. J. Clin. Invest. 96:586-596.
47. Hultman, P., L.J. Bell, S. Enestrom, and K.M. Pollard. 1992. Murine susceptibility to mercury. I. Autoantibody profiles and systemic immune deposits in inbred, congenic, and intra-H-2 recombinant strains. Clin. Immunol. Immunopathol. 65: 98-109.
48. Hultman, P., S. Enestrom, S.J. Turley, and K.M. Pollard. 1994. Selective induction of anti-fibrillarin autoantibodies by silver nitrate in mice. Clin. Exp. Immunol. 96:285-291.
49. Steen, V.D., T.A.J. Medsger, and G.P. Rodnan. 1982. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann. Intern. Med. 97:652-659.
50. Jimenez, S.A., and S.H. Sigal. 1991. A 15 year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine. J. Rheumatol. 18:1496-1503.